This internet point-of-care activity will allow learners to claim credit for using the NCCN Guidelines for Colon and Rectal Cancer.

This internet point-of-care activity will allow learners to claim credit for using the NCCN Guidelines for Colon and Rectal Cancer.

This internet point-of-care activity will allow learners to claim credit for using the NCCN Guidelines for Colon and Rectal Cancer.

This internet point-of-care activity will allow learners to claim credit for using the NCCN Guidelines for Colon and Rectal Cancer.

Neoadjuvant chemoradiation (CRT) is standard treatment for stage II–III rectal cancer. Fluoropyrimidine-based CRT prolongs disease-free survival over adjuvant CRT and improves local control over both adjuvant CRT and neoadjuvant radiotherapy alone, but does not prolong overall survival.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, patient surveillanc

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.